Search research articles
Contact Us
Filters
Showing results (51-60 of 277) with videos related to
Page
of 28
Sort By:
JCO Precision Oncology
|
September 11, 2020
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
Anita Chawla, Filip Janku, Jennifer J Wheler, et al.
BMC Cancer
|
May 30, 2015
Multiple gene aberrations and breast cancer: lessons from super-responders
Jennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Oncoscience
|
August 6, 2015
Challenges and perspective of drug repurposing strategies in early phase clinical trials
Shumei Kato, Stacy L Moulder, Naoto T Ueno, et al.
Plos One
|
November 1, 2011
BRAF mutations in advanced cancers: clinical characteristics and outcomes
Hazem El-Osta, Gerald Falchook, Apostolia Tsimberidou, et al.
Molecular Cancer Therapeutics
|
April 15, 2018
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Roman Groisberg, David S Hong, Jason Roszik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer
Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway
Floyd Christopher Holsinger, Sarina Anne Piha-Paul, Filip Janku, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 15, 2004
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study
Petr Zatloukal, Lubos Petruzelka, Milada Zemanova, et al.
Oncotarget
|
March 28, 2020
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Nicci Owusu-Brackett, Ming Zhao, Argun Akcakanat, et al.
Oncoscience
|
January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision making
Smruti J Vidwans, Michelle L Turski, Filip Janku, et al.
Page
of 28
Search research articles
Search
Showing results (51-60 of 277) with videos related to
Sort By:
Page
of 28
JCO Precision Oncology
|
September 11, 2020
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
Anita Chawla, Filip Janku, Jennifer J Wheler, et al.
BMC Cancer
|
May 30, 2015
Multiple gene aberrations and breast cancer: lessons from super-responders
Jennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Oncoscience
|
August 6, 2015
Challenges and perspective of drug repurposing strategies in early phase clinical trials
Shumei Kato, Stacy L Moulder, Naoto T Ueno, et al.
Plos One
|
November 1, 2011
BRAF mutations in advanced cancers: clinical characteristics and outcomes
Hazem El-Osta, Gerald Falchook, Apostolia Tsimberidou, et al.
Molecular Cancer Therapeutics
|
April 15, 2018
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Roman Groisberg, David S Hong, Jason Roszik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer
Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway
Floyd Christopher Holsinger, Sarina Anne Piha-Paul, Filip Janku, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 15, 2004
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study
Petr Zatloukal, Lubos Petruzelka, Milada Zemanova, et al.
Oncotarget
|
March 28, 2020
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Nicci Owusu-Brackett, Ming Zhao, Argun Akcakanat, et al.
Oncoscience
|
January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision making
Smruti J Vidwans, Michelle L Turski, Filip Janku, et al.
Page
of 28